A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in Healthy Subjects

Trial Profile

A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs TAK 831 (Primary)
  • Indications Ataxia; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 16 May 2017 Planned End Date changed from 18 May 2017 to 24 May 2017.
    • 16 May 2017 Planned primary completion date changed from 11 May 2017 to 19 May 2017.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top